Drug
Clesacostat clinical trials
Also written PF-05221304.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses clesacostat is read from its arms, and is right about nine times in ten.
Testing it · 11
- Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)CompletedPhase 2PfizerNCT04321031Written as PF-05221304
- Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic SteatohepatitisCompletedPhase 2PfizerNCT04399538Written as PF-05221304
- Effects of ACC Inhibitor on Lipid and Lipoprotein MetabolismWithdrawnPhase 1Columbia UniversityNCT04395950Written as PF-05221304
- Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)CompletedPhase 2PfizerNCT03248882Written as PF-05221304
- A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.CompletedPhase 2PfizerNCT03776175Written as PF-05221304 Monotherapy
- OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTSCompletedPhase 1PfizerNCT03871439Written as PF-05221304 Formulation A
- Study of PF-05221304 in Subjects With Varying Degrees of Hepatic ImpairmentCompletedPhase 1PfizerNCT03309202Written as PF-05221304
- Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male SubjectsCompletedPhase 1PfizerNCT03448172Written as [14C]PF-05221304
- A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese AdultsCompletedPhase 1PfizerNCT03597217Written as PF-05221304
- Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult SubjectsCompletedPhase 1PfizerNCT03534648Written as PF-05221304 administered Day 1-14
- Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy SubjectsCompletedPhase 1PfizerNCT02871037Written as PF-05221304
Codes
What other systems call clesacostat · ClinicalTrials.gg INT015400
- UNII (FDA) 752DF9PPPICLESACOSTATOne source FDA
- NCI Thesaurus C177068ClesacostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 752DF9PPPI | CLESACOSTAT | One source FDA |
| NCI Thesaurus | C177068 | Clesacostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.